Abstract
The TROVO system by Enrich Biosystems is a high-throughput, microfluidics-free platform designed to identify potent CAR-T cell clones for solid tumor therapies, including brain cancers. By employing 3D-printed hydrogel microwells, TROVO facilitates the co-culture of CAR-T cells with tumor cells, enabling real-time imaging and analysis of T cell-tumor interactions. This setup allows for the assessment of key functional metrics such as cytotoxicity and proliferation of effector cells. Advanced AI-driven software processes this data to select and retrieve high-performing T cell clones for downstream applications.
In this seminar, we demonstrated the ability to isolate tumor-reactive T cells without reliance on predefined biomarkers, streamlining the discovery of effective clones for CAR-T development. Furthermore, we showcased how this platform aids in uncovering distinct cytotoxicity-relevant pathways in 3D versus 2D cultures. This method enhances the efficiency and scalability of developing CAR-T cell therapies for solid tumors.
Highlights:
- Understand the challenge of CAR-T clone selection for solid tumors and its critical implications for therapeutic efficacy.
- Discover a streamlined method to assess T cell functionality using the TROVO system’s 3D co-culture workflow without relying on predefined biomarkers.
- See how AI-driven analysis of real-time cytotoxicity data enables reliable identification of high-performing clones, making it a scalable approach for CAR-T development.
Xiujian Ma, M.D., Ph.D.
Postdoctoral Fellow at City of Hope
Xiujian Ma, M.D., Ph.D., is a postdoctoral fellow at City of Hope. His research focuses on advancing chimeric antigen receptor (CAR) T cell therapies for brain tumors. Specifically, he investigates the interactions between CAR-T cells and the tumor microenvironment to identify actionable therapeutic targets.
